BACKGROUND: We retrospectively analyzed the 5-year biochemical disease-free survival (bDFS) and occurrence of late toxicity in prostate cancer patients treated with pencil beam scanning (PBS) proton radiotherapy. METHODOLOGY: In the period from January 2013 to June 2018, 853 patients with prostate cancer were treated with an ultra-hypofractionated schedule (36.25 GyE/five fractions). The mean PSA value was 6.7 (0.7-19.7) µg/L. There were 318 (37.3%), 314 (36.8%), and 221 (25.9%) patients at low (LR), favorable intermediate (F-IR), and unfavorable intermediate risk (U-IR), respectively. Neoadjuvant hormonal therapy was administered to 197 (23.1%) patients, and 7 (0.8%) patients had adjuvant hormonal therapy. The whole group of patients reached median follow-up time at 62.7 months, and their mean age was 64.8 (40.0-85.7) years. The bDFS rates and late toxicity profile were evaluated. RESULTS: Median treatment time was 10 (7-38) days. Estimated 5-year bDFS rates were 96.5%, 93.7%, and 91.2% for low-, favorable intermediate-, and unfavorable intermediate-risk groups, respectively. Cumulative late toxicity (CTCAE v4.0) of G2+ was as follows: gastrointestinal (GI)-G2: 9.1%; G3: 0.5%; genitourinary (GU)-G2: 4.3%, and no G3 toxicity was observed. PSA relapse was observed in 58 (6.8%) patients: 16 local, 22 lymph node, 4 bone recurrences, and 10 combined sites of relapse were detected. Throughout the follow-up period, 40 patients (4.7%) died, though none due to prostate cancer. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy is an effective treatment for low- and favorable intermediate-risk prostate cancer, with long-term bDFS rates comparable to other techniques. It is promising for unfavorable intermediate-risk prostate cancer and has acceptable long-term GI and favorable GU toxicity.

Department of Health Care Disciplines and Population Protection Faculty of Biomedical Engineering Czech Technical University Prague Sítná Square 3105 272 01 Kladno Czech Republic

Department of Oncology 1st Faculty of Medicine and General University Hospital Charles University Kateřinská 32 121 08 Praha Czech Republic

Proton Therapy Center Czech Budínova 1a 180 00 Prague Czech Republic

Value Outcomes Ltd Václavská 316 12 120 00 Praha Czech Republic

See more in PubMed

Kole T.P., Nichols R.C., Lei S., Wu B., Huh S.N., Morris C.G., Lee S., Tong M., Mendenhall N.P., Dritschilo A., et al. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol. 2015;54:825–831. doi: 10.3109/0284186X.2014.953260. PubMed DOI

Kubeš J., Haas A., Vondráček V., Andrlík M., Navrátil M., Sláviková S., Vítek P., Dědečková K., Prausová J., Ondrová B., et al. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2021;110:1090–1097. doi: 10.1016/j.ijrobp.2021.02.014. PubMed DOI

Kubeš J., Vondráček V., Andrlik M., Navrátil M., Sláviková S., Vítek P., Rosina J., Abrahámová J., Prausová J., Grebenyuk A., et al. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry acute toxicity and preliminary results. J. Med. Imaging Radiat. Oncol. 2019;63:829–835. doi: 10.1111/1754-9485.12947. PubMed DOI

Roach M., 3rd, Hanks G., Thames H., Jr., Schellhammer P., Shipley W.U., Sokol G.H., Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006;65:965–974. doi: 10.1016/j.ijrobp.2006.04.029. PubMed DOI

R Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2023. [(accessed on 1 May 2023)]. Available online: https://www.R-project.org/

Kishan A.U., Dang A., Katz A.J., Mantz C.A., Collins S.P., Aghdam N., Chu F.I., Kaplan I.D., Appelbaum L., Fuller D.B., et al. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw. Open. 2019;2:e188006. doi: 10.1001/jamanetworkopen.2018.8006. PubMed DOI PMC

Katz A.J., Kang J. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study. Front. Oncol. 2014;4:301. doi: 10.3389/fonc.2014.00301. PubMed DOI PMC

Fuller D.B., Crabtree T., Kane B.L., Medbery C.A., Pfeffer R., Gray J.R., Peddada A., Royce T.J., Chen R.C. High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results from a Mature Multi-Institutional Clinical Trial. Front. Oncol. 2022;12:935310. doi: 10.3389/fonc.2022.935310. PubMed DOI PMC

Takagi M., Demizu Y., Fujii O., Terashima K., Niwa Y., Daimon T., Tokumaru S., Fuwa N., Hareyama M., Okimoto T. Proton Therapy for Localized Prostate Cancer: Long-Term Results from a Single-Center Experience. Int. J. Radiat. Oncol. Biol. Phys. 2021;109:964–974. doi: 10.1016/j.ijrobp.2020.11.007. PubMed DOI

Henderson R.H., Bryant C., Hoppe B.S., Nichols R.C., Mendenhall W.M., Flampouri S., Su Z., Li Z., Morris C.G., Mendenhall N.P. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol. 2017;56:963–970. doi: 10.1080/0284186X.2017.1287946. PubMed DOI

Grewal A.S., Schonewolf C., Min E.J., Chao H.H., Both S., Lam S., Mazzoni S., Bekelman J., Christodouleas J., Vapiwala N. Four-Year Outcomes from a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019;105:713–722. doi: 10.1016/j.ijrobp.2019.05.069. PubMed DOI

Slater J.M., Slater J.D., Kang J.I., Namihas I.C., Jabola B.R., Brown K., Grove R., Watt C., Bush D.A. Hypofractionated, Proton Therapy in Early, Prostate Cancer: Results of a Phase I/II Trial at Loma Linda University. Int. J. Part. Ther. 2019;6:1–9. doi: 10.14338/IJPT-19-00057. PubMed DOI PMC

Vargas C.E., Schmidt M.Q., Niska J.R., Hartsell W.F., Keole S.R., Doh L., Chang J.H., Sinesi C., Rodriquez R., Pankuch M., et al. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. Adv. Radiat. Oncol. 2018;3:322–330. doi: 10.1016/j.adro.2018.02.004. PubMed DOI PMC

Ha B., Cho K.H., Lee K.H., Joung J.Y., Kim Y.J., Lee S.U., Kim H., Suh Y.G., Moon S.H., Lim Y.K., et al. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: Moderate versus extreme hypofractionation. Radiat. Oncol. 2019;14:4. doi: 10.1186/s13014-019-1210-7. PubMed DOI PMC

Miszczyk M., Szołtysik M., Hasterok M., Goldner G., Rajwa P., Namysł-Kaletka A., Napieralska A., Kraszkiewicz M., Stąpór-Fudzińska M., Tomasik B., et al. Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk. Biomedicines. 2022;10:2446. doi: 10.3390/biomedicines10102446. PubMed DOI PMC

Bao A., Barsky A.R., Maxwell R., Bekelman J.E., Both S., Christodouleas J.P., Deville C., Jr., Fang P., Tochner Z.A., Vapiwala N. Long-term Clinical, Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy. Int. J. Part. Ther. 2021;8:14–24. doi: 10.14338/IJPT-21-00016. PubMed DOI PMC

Urso L., Rocca G.C., Borgia F., Lancia F., Malorgio A., Gagliano M., Zanetto M., Uccelli L., Cittanti C., Ippolito C., et al. The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach. Biomedicines. 2022;10:2463. doi: 10.3390/biomedicines10102463. PubMed DOI PMC

Surasi D.S., Eiber M., Maurer T., Preston M.A., Helfand B.T., Josephson D., Tewari A.K., Somford D.M., Rais-Bahrami S., Koontz B.F., et al. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3 Prospective Multicentre Study (LIGHTHOUSE) Eur. Urol. 2023. ahead of print . PubMed DOI